BCYC — Bicycle Therapeutics Share Price
0.000.00%
Last trade - 00:00- $865.85m
- $439.65m
- $26.98m
- 48
- 10
- 78
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.47 | ||
| Price to Tang. Book | 2.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 21.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.14% | ||
| Return on Equity | -56.13% | ||
| Operating Margin | -432.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.8 | 10.39 | 11.7 | 14.46 | 26.98 | 38.45 | 28.89 | 30.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 27th, 2017
- Public Since
- May 23rd, 2019
- No. of Shareholders
- 45
- No. of Employees
- 284
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 42,779,030
- Address
- Blocks A & B, Portway Building, Granta P, CAMBRIDGE, CB21 6GS
- Web
- https://www.bicycletherapeutics.com/
- Phone
- +44 1223261503
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for BCYC
Q3 2024 Bicycle Therapeutics PLC Earnings Release
Similar to BCYC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Bicycle Therapeutics share price?
As of Today at 19:36 UTC, shares in Bicycle Therapeutics are trading at $20.53. This share price information is delayed by 15 minutes.
How has the Bicycle Therapeutics share price performed this year?
Shares in Bicycle Therapeutics last closed at $20.53 and the price had moved by -23.77% over the past 365 days. In terms of relative price strength the Bicycle Therapeutics share price has underperformed the S&P500 Index by -39.34% over the past year.
What are the analyst and broker recommendations for Bicycle Therapeutics?
The overall consensus recommendation for Bicycle Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bicycle Therapeutics dividend yield?
Bicycle Therapeutics does not currently pay a dividend.
Does Bicycle Therapeutics pay a dividend?
Bicycle Therapeutics does not currently pay a dividend.
When does Bicycle Therapeutics next pay dividends?
Bicycle Therapeutics does not currently pay a dividend.
How do I buy Bicycle Therapeutics shares?
To buy shares in Bicycle Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bicycle Therapeutics?
As of the previous close price of $20.53, shares in Bicycle Therapeutics had a market capitalisation of $878.25m.
Where are Bicycle Therapeutics shares listed?
Here are the trading details for Bicycle Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BCYC
What kind of share is Bicycle Therapeutics?
Based on an overall assessment of its quality, value and momentum Bicycle Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bicycle Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Bicycle Therapeutics is $41.33. That is 101.32% above the last closing price of $20.53.
Analysts covering Bicycle Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.41 for the next financial year.
What is the trend in the Bicycle Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bicycle Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -3.92%.
As of the last closing price of $20.53, shares in Bicycle Therapeutics were trading +1.74% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bicycle Therapeutics PE Ratio?
The Bicycle Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $20.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bicycle Therapeutics?
We do not have data on Bicycle Therapeutics' directors